EUCTR2019-004805-28-NL进行中（未招募）1 期
What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants? - WOEST 3 trial
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Over 18 years of age
- •Acute coronary syndrome with elevated cardiac enzymes
- •Atrial fibrillation with long-term indication for oral anticoagulation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1500
排除标准
- •Severe bleeding in past 3 months
- •Known coagulopathy
- •Contra-indications for intended medication (NOAC, P2Y12-remmer, ASA)
- •eGFR < 15 min/kg/1.73m2
研究者
相似试验
撤回
4 期
What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants?myocardial infarctionNL-OMON49131Sint Antonius Ziekenhuis2,500
招募中
1 期
WOEST-3Atrial fibrillationAcute coronary syndromeChronic coronary syndromeCTIS2022-502140-13-00St Antonius Hospital2,550
进行中（未招募）
1 期
What is the optimal strategy of blood thinners in patients with atrial fibrillation and a heart attack or coronary stent?EUCTR2022-001298-30-NLSt. Antonius Hospital2,000
招募中
4 期
What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention?coronary artery disease10011082atrial fibrillationNL-OMON51815Sint Antonius Ziekenhuis1,500
尚未招募
Unknown
Optimal antithrombotic strategy for treatment of atherosclerotic cardiovascular disease – comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study)KCT0008458Seoul National University Bundang Hospital2,758